The water-soluble crystallins from normal human lenses (n = 32), cataractous lenses of diabetic patients (n = 9) and cataractous lenses of nondiabetic patients (n = 9) were analyzed with fast-performance liquid chromatography. Six different crystallin classes were separated reproducibly by chromatography on Superose 6. The fractions were identified as αH, αL, βH, βL1, βL2 and low-molecular-weight (LMW) crystallins by their elution order and molecular mass. The results obtained show that during lens aging there is a progressive increase in αH-crystallm and a decrease in αL-crystallin content, while no significant age-related changes were observed in the LMW fraction. Analysis of changes in crystallin content in human cataractous lenses showed that apparently cataractogenesis can be described as an acceleration of the normal aging process. Important differences were found between the chromatographic profiles of cataracts from diabetic and nondiabetic patients mainly in the LMW fraction, suggesting that in cataract formation of diabetics alternative mechanisms may be superimposed on the normal aging process.

Keywords:
Aging, Cataract, Chromatography, Crystallins, Diabetes, Lens
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.